SCHEMBL6841919

SCHEMBL6841919

CCOc1ccc(C2=NN(Cc3ccc(NC(=O)c4ccc[nH]4)cc3)C(=O)OC2CC)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 11/20 0.39
PDE4A P27815 8/20 0.39
PDE4B Q07343 8/20 0.39
PDE4C Q08493 8/20 0.39
GAA P10253 1/20 0.38
CFTR P13569 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
AXL P30530 1/20 0.37
MERTK Q12866 1/20 0.37
INSR P06213 2/20 0.37
ALK Q9UM73 2/20 0.37
SCN9A Q15858 1/20 0.36
ITGB3 P05106 1/20 0.36
ITGAV P06756 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6655877 0.97 PDE4D (0.39) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6660061 0.95 PDE4D (0.43) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6655532 0.95 PDE4D (0.39) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6661238 0.93 PDE4D (0.38) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6655606 0.91 GAA (0.39) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6662424 0.91 PDE4D (0.38) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6659784 0.91 GAA (0.38) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6657033 0.89 PDE4D (0.38) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6656279 0.89 PDE4D (0.38) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL6661778 0.88 PDE4A (0.42) PDE4DPDE4APDE4BPDE4CGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.